Pharmac has added several new consultations to its Find activities page, including November items on lithium carbonate, prasugrel tablets and medical devices.
The consultation finder shows 17 results under the heading "Find activities - 17 results - Pharmac Consultations - Citizen Space" on the Pharmac Consultations site.
Lithium carbonate brand change proposal
A consultation titled "Proposal to change lithium carbonate 250 mg brand" is listed as having "Opened 19 November 2026" on the finder.
In the summary, Pharmac says, "The current brand of lithium carbonate 250 mg capsules (Douglas) is being discontinued." It states that Pharmac is proposing to replace the Douglas brand with Lithium Carbonate Essential Pharma tablets "to ensure people still have access to a 250 mg strength presentation of lithium."
The same summary notes that "The Douglas brand would remain funded for a transition period of five...", although the visible text in the list truncates after "five" on the consultation finder.
These changes could affect how mental health treatment is split between public funding and health insurance, alongside any life insurance policies that consider ongoing medication use.
LifeHealthcare medical devices listing proposal
A separate consultation titled "Proposal to list medical devices supplied by LifeHealthcare Limited" is marked as "Opened 18 November 2026" on the finder.
Pharmac says it is seeking feedback on "a proposal to list medical devices supplied by LifeHealthcare Limited in the surgical implants, and medical and surgical instruments and power tools, and adhesives sealants and haemostats categories under Part III of Section H of the Pharmaceutical Schedule from 1 February 2027." The summary states that products listed "would give Health NZ more options for medical devices in these categories."
Any change in the types of implants and instruments used in public hospitals can influence what is treated through the public system versus what may be claimed on health insurance or ACC cover.
Prasugrel tablets funding proposal
The finder also lists a consultation titled "Proposal to fund prasugrel tablets", with a status line "Opened 12 November 2026" linking to the prasugrel item on Pharmac’s site.
Pharmac states, "We are proposing to fund prasugrel tablets (5 mg and 10 mg) in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2027 for use in both the community and Health New Zealand | Te Whatu Ora (Health NZ) hospitals."
Prasugrel is described in the summary as used in combination with aspirin, helping prevent blood clots and cardiovascular events including heart attack and stroke in people with acute coronary syndrome (ACS), though the list view truncates the final sentence on the finder.
Funding a cardiovascular medicine for both community and hospital use can change long-term treatment patterns that may interact with income protection, trauma cover and TPD cover.
Other related November schedule items
The same page lists "Changes to the Practitioner Supply Order (PSO) list and rules", which seeks feedback on "a proposal to expand the Practitioner Supply Order (PSO) list and to amend the Schedule General Rules to clarify the intended use of PSO supplies from 1 November 2026." This consultation appears on the PSO page and is also summarised in the finder.
Another consultation, "Proposal to fund sexual health products", is shown as "Closed 20 November 2026" and seeks feedback on a proposal to fund the Cupid brand of internal condoms and water-based lubricant sachets in the community from 1 April 2027, according to its listing on the Pharmac site.
These consultations form part of the wider set of 17 activities visible on Pharmac’s consultation finder, which also includes proposals on febuxostat for gout, medicines for high blood pressure and bacterial infections, the 2026/27 tender, vaccines and other policy reviews, all of which sit in the background for insurer news and regulation news tracked alongside premiums news on QuoteHub’s Premium Index.



